Literature DB >> 15507950

Intrapartum fetal heart rate monitoring in cases of cytomegalovirus infection.

Masatoki Kaneko1, Hiroshi Sameshima, Tomoaki Ikeda, Tsuyomu Ikenoue, Toshio Minematsu.   

Abstract

OBJECTIVE: Several studies have shown that abnormal intrapartum fetal heart rate patterns are the results from pre-existing fetal brain damage. We evaluated intrapartum fetal heart rate pattern of cytomegalovirus-infected fetuses and correlated the patterns with neurologic outcomes. STUDY
DESIGN: Between 1991 and 2001, there were 20 cytomegalovirus-infected fetuses. We selected 40 fetuses as control subjects that were matched for gestational age and birth weight. Fetal heart rate was interpreted according to the guidelines of the National Institute for Child and Human Development. The incidence of abnormal fetal heart rate pattern and umbilical blood gases were compared between both groups. We also investigated the factors that contributed to abnormal fetal heart rate pattern in the cytomegalovirus group.
RESULTS: Nonreassuring fetal heart rate patterns (prolonged deceleration and recurrent late deceleration) were observed in 8 of 20 fetuses (prolonged deceleration, 7 fetuses; recurrent late deceleration, 1 fetus) in the cytomegalovirus group and in 3 of 41 fetuses (prolonged deceleration, 1 fetus; recurrent late deceleration, 2 fetuses) in the control group (P<.05, Fisher test). Baseline fetal heart rate variability was minimal in 4 of the 7 prolonged deceleration cases in the cytomegalovirus group. Umbilical pH <7.1 was found for 1 fetus in the cytomegalovirus group. The average umbilical arterial pH values were similar in both the groups. In the cytomegalovirus group, there were no differences in the incidence of contributing factors between 8 fetuses with abnormal fetal heart rate pattern (prolonged deceleration and recurrent late deceleration) and 8 fetuses with no change. There were 3 fetuses with cerebral palsy: 2 fetuses in the no change group and 1 fetus in the prolonged deceleration group. Antigenemia was positive exclusively in 4 cases with abnormal fetal heart rate pattern (P<.05).
CONCLUSION: Cytomegalovirus-infected fetuses are more likely to show abnormal intrapartum fetal heart rate patterns than low-risk control fetuses, which suggests that the perinatal detection of cytomegalovirus is necessary to distinguish hypoxic-ischemic encephalopathy.

Entities:  

Mesh:

Year:  2004        PMID: 15507950     DOI: 10.1016/j.ajog.2004.03.015

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Correlation between fetal heart rate evolution patterns and magnetic resonance imaging findings in severe cerebral palsy: A longitudinal study.

Authors:  Masahiro Nakao; Yukiko Nanba; Asumi Okumura; Junichi Hasegawa; Satoshi Toyokawa; Kiyotake Ichizuka; Naohiro Kanayama; Shoji Satoh; Nanako Tamiya; Akihito Nakai; Keiya Fujimori; Tsugio Maeda; Hideaki Suzuki; Mitsutoshi Iwashita; Akira Oka; Tomoaki Ikeda
Journal:  BJOG       Date:  2022-02-13       Impact factor: 7.331

2.  Low Maternal Immunoglobulin G Avidity and Single Parity as Adverse Implications of Human Cytomegalovirus Vertical Transmission in Pregnant Women with Immunoglobulin M Positivity.

Authors:  Masatoki Kaneko; Junsuke Muraoka; Kazumi Kusumoto; Toshio Minematsu
Journal:  Viruses       Date:  2021-05-09       Impact factor: 5.048

3.  Association between exposure to air pollution during pregnancy and false positives in fetal heart rate monitoring.

Authors:  Seiichi Morokuma; Takehiro Michikawa; Shin Yamazaki; Hiroshi Nitta; Kiyoko Kato
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

4.  Non-reassuring foetal status and neonatal irritability in the Japan Environment and Children's Study: A cohort study.

Authors:  Seiichi Morokuma; Takehiro Michikawa; Kiyoko Kato; Masafumi Sanefuji; Eiji Shibata; Mayumi Tsuji; Ayako Senju; Toshihiro Kawamoto; Shouichi Ohga; Koichi Kusuhara
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.